Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Colorectal Cancer: Update Bulletin [November 2014]

Product Code:
596200308
Condition:
New
Release Date:
November 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Colorectal Cancer: ESMO 2014, Taiho Oncology’s TAS-102, RECOURSE trial; Mologen’s MGN 1703, IMPACT and IMPALA trials; XBiotech’s Xilonix, metastatic CRC-related cachexia; Boehringer Ingelheim’s nintedanib, LUME-COLON 1 trial; AVEO Pharmaceutical’s tivozanib, BATON-CRC trial.

Highlights from this event update bulletin

  • How likely is FDA approval of Taiho Oncology’s TAS-102, and what impact will its approval have on Bayer and Sanofi’s Stivarga?
  • What is the likely outcome of the IMPALA trial and what will it mean for Mologen’s MGN 1703?
  • What is the clinical and commercial potential of XBiotech’s Xilonix?
  • What is the likely outcome of the LUME-COLON 1 trial, and how will it impact the development of Boehringer Ingelheim’s nintedanib?
  • What is the significance of the BATON-CRC trial results and what impact will they have on the development of AVEO Pharmaceutical’s tivozanib?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved